IP Library Granted Patent US 8,138,157
Granted Patent B2
US 8,138,157 · App. 12/758,602 · Granted Mar 20, 2012

Antibiotic formulation and method of treatment

Assignee: Flow Pharma, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,138,157
App. No.
12/758,602
Granted
Mar 20, 2012
Kind
B2
Abstract

A formulation comprised of particles which may be in groups and are comprised of a biocompatible polymer and an antimicrobial drug for controlled release of the drug is disclosed. The particles may be in an aqueous solution comprising thrombin and be dispersed in a gel. The formulation is administered to an area such as an open wound having an orthopedic implant therein and provides a therapeutically effective level of drug to the patient over therapeutically effective period of time.

Claims (35)

1. A method of treating osteomyelitis, comprising:

implanting an orthopedic implant into a surgical wound site;

administering to the wound site a formulation comprised of a plurality of particles which particles are comprised of an antimicrobial drug and a biocompatible polymer; and

allowing drug from the formulation to dissolve into the wound site over a period of time not less than one day and not more than seven days and provide a therapeutically effective dose of the drug over the period of time to thereby treat osteomyelitis.

2. The method of claim 1 , wherein the therapeutically effective dose is in a range of 30 micrograms per milliliter±25 micrograms per milliliter and the period of time is 72 hours±12 hours.

3. The method of claim 2 , wherein the therapeutically effective dose is at substantially undetectable levels at more than 5 cm from the wound cite.

4. The method of claim 1 , further comprising:

administering thrombin to the wound cite.

5. The method of claim 1 , wherein the formulation comprises:

a first group of spherical particles comprising 100 or more particles wherein each particle of the first group has the same diameter as other particles in the first group with a margin of error of ±10% or less;

a second group of spherical particles comprising 100 or more particles wherein each particle of the second group has the same diameter as other particles in the second group with a margin of error of ±10% or less;

wherein particles of the first group dissolve at a rate which is faster than a rate at which the particles of the second group dissolve and the formulation provides from 5 mcg/ml to 100 mcg/ml of antimicrobial drug to a target area.

6. The method of claim 5 , wherein the formulation further comprises:

a third group of spherical particles comprising 100 or more particles wherein each particle of the third group has the same diameter as other particles in the third group with a margin of error of ±10% or less;

wherein particles of the third group dissolve at a rate different from a rate at which the particles of the first and second groups dissolve.

7. The method of claim 1 , wherein the biocompatible polymer is polylactic glycolic acid (PLGA), the antimicrobial is an amino glycoside, and the particles are dispersed in a gel.

8. The method of claim 5 , wherein the formulation further comprises:

a plurality of additional groups of spherical particles comprising 100 or more particles wherein the particles of each additional group has the same diameter as other particles in that group with a margin of error of ±20% or less;

wherein particles of each additional group dissolve at a rate different from a rate at which the particles of other groups dissolve.

9. The method of claim 6 ,

wherein the second group of particles have 1,000 square centimeters or more of surface area per 0.1 cm 3 of total particle volume per group of particles more than the first group of particles; and

wherein the third group of particles have 2,000 square centimeters or more of surface area per 0.1 cm 3 of total particle volume per group of particles more than the second group of particles.

10. The method of claim 6 ,

wherein the second group of particles have 5,000 square centimeters or more of surface area per 0.1 cm 3 of total particle volume per group of particles more than the first group of particles; and

wherein the third group of particles have 10,000 square centimeters or more of surface area per 0.1 cm 3 of total particle volume per group of particles more than the second group of particles.

11. The method of claim 8 , wherein the particles of each group dissolve at a rate per unit of time which is different from a rate of dissolution of any other of the groups of particles by an amount of about 25% or more.

12. The method of claim 1 , wherein the antimicrobial drug is gentamicin and the particles are in an aqueous solution comprising thrombin.

13. The method of claim 8 , wherein the spherical particles in each group have a diameter in a range of from about 40 micrometers to about 2 micrometers.

14. The method of claim 8 , wherein the spherical particles in each group have a diameter in a range of from about 30 micrometers to about 4 micrometers.

15. The method of claim 6 ,

wherein the second group of particles have 1,000 square centimeters or more of surface area per 0.1 cm 3 of total particle volume per group of particles more than the first group of particles; and

wherein a third group of particles have 2,000 square centimeters or more of surface area per 0.1 cm 3 of total particle volume per group of particles more than the second group of particles.

16. The method of claim 6 ,

wherein the second group of particles have 5,000 square centimeters or more of surface area per 0.1 cm 3 of total particle volume per group of particles more than the first group of particles; and

wherein a third group of particles have 10,000 square centimeters or more of surface area per 0.1 cm 3 of total particle volume per group of particles more than the second group of particles.

Assignments (5)
SECURITY INTEREST Recorded Sep 13, 2023
From: FLOW PHARMA, INC.
To: JOHN C. BRADY, TRUSTEE OF THE JCB TRUST DATED AUGUS 22, 2019
Reel/Frame 064894/0189 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 6, 2018
From: DARVEL ANTIBIOTICS, LLC
To: FLOW PHARMA, INC.
Reel/Frame 046284/0559 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 20, 2015
From: FLOW PHARMA, INC.
To: DARVEL ANTIBIOTICS, LLC
Reel/Frame 036137/0312 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 8, 2012
From: FLOW FOCUSING, INC.
To: FLOW PHARMA, INC.
Reel/Frame 027672/0602 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 27, 2010
From: RUBSAMEN, REID M.
To: FLOW FOCUSING, INC.
Reel/Frame 025048/0054 →
Continuity (9)
Continuation 11749369 · May 16, 2007
Continuation In Part 11383562 · May 16, 2006
Continuation In Part 10618255 · Jul 10, 2003
Continuation In Part 10195046 · Jul 12, 2002
Provisional Application 60821668 · Aug 7, 2006
Provisional Application 60805267 · Jun 20, 2006
Provisional Application 60326675 · Oct 2, 2001
Provisional Application 60305364 · Jul 13, 2001
Related Publication 20100291220A1 · Nov 18, 2010